The putative anti‐tumor activity of infliximab (anti‐TNF antibody) was demonstrated in advanced RCC,42 but a subsequent phase I/II trial using a combination of infliximab and the multi‐kinase inhibitor sorafenib showed adverse events with lack of efficacy.43 Our data indicate that blocking TNFR2 may account for adverse outcomes and suggest that a TNFR2 agonist combined with standard chemotherapy regimens may offer greater efficacy. Here, TNFRSF1B is linked to neoplasm.